Bicycle Therapeutics Ltd.
Two-wheeled constrained peptides
This article was originally published in Start Up
Natural peptides have plenty of drawbacks that have held them back when it comes to pharmaceutical applications: their highly unstable amino acid chains degrade too quickly to produce a therapeutic effect, discovery has been difficult to industrialize, and manufacturing complex and costly. However, emerging technologies for synthetically stabilizing peptide structures may eventually conquer most of natural peptides’ drawbacks as pharmaceuticals. Bicycle Therapeutics Ltd. hopes its two-wheel “constrained” peptides it calls “bicycles” will ride off with the prize for exploiting nature’s medicines.
You may also be interested in...
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.